Impact of Drug Price Revisions and Dispensing Fee Revisions
First written in FY2016. 14 of 22 entries say "Materialised", first in FY2017-Q1. Latest entry: 2026-08-07.
Qol Holdings moved to the "Worse" side of this theme in 2016, 10 years before the typical company in this theme (2026).
1 other company's latest entry also says "Mitigated".
- FY2026-H1MitigatedAnnual report
「In the pharmacy business, the unit price of professional fees has increased as the acquisition of the medical DX promotion system preparation fee, newly established in the dispensing fee revision implemented in the previous fiscal year, progressed, and the proportion of generic medicines used increased.」
In contrast to the previously described declines in unit prices due to dispensing fee revisions and other factors, this time it states that unit prices for technical fees increased due to the acquisition of the medical DX add-on and other factors, as well as an increase in the percentage of generic drugs used. - FY2025-H1MitigatedAnnual report
「In addition, unit prices for technical fees increased following the dispensing fee revision in June, resulting in increases in recent revenue and operating income.」
In contrast to the previous descriptions of declines in unit prices due to drug price and dispensing fee revisions, this time it states that unit prices for technical fees increased following the dispensing fee revision in June, and that recent revenue and operating income increased. - FY2024-Q3MaterialisedAnnual report
「Meanwhile, unit prices for drug fees and technical fees have declined due to the drug price revision and the end of transitional measures, including those related to the regional support system add-on under the dispensing fee revision.」
The end of transitional measures related to the drug price and dispensing fee revisions, among other factors, has resulted in actual declines in unit prices for drug fees and technical fees. - FY2024-Q2MaterialisedAnnual report
「Meanwhile, unit prices for drug fees and technical fees have declined due to the drug price revision and the end of transitional measures, including those related to the regional support system add-on under the dispensing fee revision.」
The end of transitional measures related to the drug price and dispensing fee revisions, among other factors, resulted in declines in unit prices for drug fees and technical fees in the current quarter as well. - FY2024-Q1MaterialisedAnnual report
「Meanwhile, unit prices for drug fees and technical fees have declined due to the drug price revision and the end of transitional measures, including those related to the regional support system add-on under the dispensing fee revision.」
The end of transitional measures related to the drug price and dispensing fee revisions has resulted in actual declines in unit prices for drug fees and technical fees. - FY2023-Q3MaterialisedAnnual report
「As for performance, although the number of prescriptions processed increased due to contributions from M&A and new store openings carried out in the previous fiscal year, as well as the promotion of home and institutional dispensing, unit prices for drug fees and technical fees decreased due to the impact of the drug price revision and the dispensing fee revision.」
The number of prescriptions processed increased due to the impact of the drug price and dispensing fee revisions, while unit prices for drug fees and technical fees continued to decline. - FY2023-Q2MaterialisedAnnual report
「Pharmaceutical fee and technical fee unit prices declined due to the impact of revisions to drug prices and dispensing fees, while the number of prescriptions processed recently increased.」
The decline in pharmaceutical fee and technical fee unit prices occurred as a result of the revisions to drug prices and dispensing fees. - FY2023-Q1MaterialisedAnnual report
「While the contribution of M&A and new store openings carried out in the previous fiscal year, together with the promotion of home and institutional dispensing services, increased the number of prescriptions processed, pharmaceutical fee and technical fee unit prices declined due to the impact of revisions to drug prices and dispensing fees.」
The decline in pharmaceutical fee and technical fee unit prices occurred as a result of the revisions to drug prices and dispensing fees. - FY2022RestatedAnnual report
「If dispensing fees and drug prices are revised in the future and the fee points, amounts or other figures for dispensing fees and drug prices change, this could affect the Group’s business performance and other results.」
The company continues to disclose the impact on business performance from changes in fee points and amounts for dispensing fees and drug prices as a risk. - FY2021RestatedAnnual report
「If dispensing fees and drug prices are revised in the future and the fee points, amounts or other figures for dispensing fees and drug prices change, this could affect the Group’s business performance and other results.」
The company continues to disclose the impact on business performance from changes in fee points and amounts resulting from revisions to dispensing fees and drug prices as a risk. - FY2019MaterialisedAnnual report
「Despite the significant impact of revisions to dispensing fees and drug prices on business performance, the company pursued active M&A, including the acquisition in January 2019 of shares in 株式会社ニチホス, which operates 25 stores mainly in the Kansai region. As a result, revenue declined ¥962 million year on year to ¥134,122 million (down 0.7%), while operating profit declined ¥2,303 million to ¥6,349 million (down 26.6%).」
The significant impact of revisions to dispensing fees and drug prices was reflected in the health insurance pharmacy business, and operating profit declined 26.6% year on year. - FY2019-Q3MaterialisedAnnual report
「In April 2018, medical service fees and drug prices were revised in the health insurance pharmacy industry. The revision was particularly challenging for major pharmacy chains due to, among other factors, a reassessment of large pharmacies located near major hospitals.」
The severe impact of the April 2018 revisions to dispensing fees and drug prices continued, and operating profit in the health insurance pharmacy business declined 29.3% year on year. - FY2019-Q2MaterialisedAnnual report
「In April 2018, medical service fees and drug prices were revised in the health insurance pharmacy industry. The revision was particularly challenging for major pharmacy chains due to, among other factors, a reassessment of large pharmacies located near major hospitals.」
The April 2018 revisions to dispensing fees and drug prices had a severe impact on major pharmacy chains, and their significant impact continued in the health insurance pharmacy business during the quarter. - FY2019-Q1MaterialisedAnnual report
「In pharmacy operations, the company focused on promoting the use of generic drugs despite the impact of revisions to medical service fees and drug prices. As a result, revenue declined ¥776 million year on year to ¥32,042 million (down 2.4%), and operating profit declined ¥487 million to ¥1,287 million (down 27.5%).」
The impact of the April 2018 revisions to medical service fees and drug prices continued to affect the health insurance pharmacy business, resulting in a 27.5% year-on-year decline in operating profit. - FY2017MaterialisedAnnual report
「Due to the impact of revisions to drug prices and medical service fees, pharmaceutical fee and technical fee unit prices declined, and operating profit fell ¥550 million year on year to ¥6,161 million (down 8.2%).」
For the full year, pharmaceutical fee and technical fee unit prices declined due to revisions to drug prices and medical service fees, while operating profit in the health insurance pharmacy business also declined. - FY2017-Q3MaterialisedAnnual report
「Due to the impact of the revision of medical service fees, technical fee unit prices declined, and operating profit fell ¥636 million year on year to ¥3,969 million (down 13.8%).」
The decline in technical fee unit prices due to the revision of medical service fees continued, and operating profit in the health insurance pharmacy business declined 13.8% year on year. - FY2017-Q2MaterialisedAnnual report
「Due to the impact of the revision of medical service fees, operating profit declined ¥731 million year on year to ¥1,980 million (down 27.0%).」
The revision of medical service fees resulted in a 27.0% year-on-year decline in operating profit for the health insurance pharmacy business for the six months ended Q2. - FY2017-Q1MaterialisedAnnual report
「Profit was affected by the immediate impact of the revision, with operating profit declining ¥456 million year on year to ¥770 million (down 37.2%).」
The April 2016 revision of dispensing fees and drug prices resulted in a 37.2% year-on-year decline in operating profit in the health insurance pharmacy business. - FY2016First statedAnnual report
「If drug prices and dispensing fees are revised in the future and the fee points or other amounts for drug prices and dispensing fees change, this could affect the Group’s business performance and other results.」
The company disclosed changes in official prices and fee schedules as a risk to business performance.